Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

1. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Signal - Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Dissemination Centre Discover Portal NIHR DC Discover Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Published on 11 December (...) 2015 This follow up study examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil. However

NIHR Dissemination Centre2018

2. Donepezil

Donepezil Top results for donepezil - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for donepezil The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

3. Donepezil for dementia due to Alzheimer's disease.

Donepezil for dementia due to Alzheimer's disease. BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor.This review is an updated (...) version of a review first published in 1998. OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healthcare resource use and costs. SEARCH METHODS: We searched Cochrane Dementia and Cognitive Improvement's Specialized Register, MEDLINE, Embase, PsycINFO and a number of other sources on 20 May 2017

Cochrane2018

4. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive NIHR DC | Signal - Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive (...) Published on 11 December 2015 This follow up study examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil

NIHR Dissemination Centre2018

5. Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules

Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules U.S. Department of Health and Human Services Search FDA Submit search Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Company: Forest Laboratories, Inc. Application No.: 206439 Approval Date: 12/23/2014

FDA - Drug Approval Package2014

6. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | Evidence-Based Medicine This site uses cookies. By continuing to browse the site (...) you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cessation of donepezil is associated with clinical decline in patients with moderate

Evidence-Based Medicine (Requires free registration)2013

7. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Hartz S, Getsios D, Tao S, Blume S, Maclaine G Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of donepezil, for the treatment of Alzheimer’s disease, versus memantine or no treatment, in Germany. The authors concluded that donepezil was highly cost-effective. The methods were appropriate

NHS Economic Evaluation Database.2013

10. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial

Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial 22829268 2012 07 25 2012 10 24 2016 12 15 1531-8249 72 1 2012 Jul Annals of neurology Ann. Neurol. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. 41-52 10.1002/ana.23557 Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled (...) exploratory phase 2 trial. One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, or 10 mg of donepezil hydrochloride daily for 12 weeks (n = 35, 35, 33, and 37, respectively). Effects on cognitive function were assessed using the Mini-Mental State Examination (MMSE) and several domain-specific neuropsychological tests. Changes in behavior were evaluated using the Neuropsychiatric Inventory, caregiver burden using the Zarit

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

11. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22711111 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jun 19;156(12):JC6-10. doi: 10.7326/0003-4819-156-12-201206190-02010. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 1 . 1 St. Vincent's Health Network

Annals of Internal Medicine2012

12. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content

NIHR HTA programme2012

13. Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Donepezil and memantine for moderate-to-severe Alzheimer's disease. 22397651 2012 03 08 2012 03 16 2016 11 22 1533-4406 366 10 2012 Mar 08 The New England journal of medicine N. Engl. J. Med. Donepezil and memantine for moderate-to-severe Alzheimer's disease. 893-903 10.1056/NEJMoa1106668 Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression (...) to moderate-to-severe disease. We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received

NEJM2012

14. Significant Dose Differences in Donepezil Purchased From the United States and Canada

Significant Dose Differences in Donepezil Purchased From the United States and Canada 21844564 2011 08 16 2011 10 06 2016 10 19 1539-3704 155 4 2011 Aug 16 Annals of internal medicine Ann. Intern. Med. Significant dose differences in donepezil purchased from the United States and Canada. 279-80 10.7326/0003-4819-155-4-201108160-00026 Wang Chong-Zhi CZ Du Guang-Jian GJ Zhen Zhong Z Calway Tyler T Yuan Chun-Su CS eng K01 AT005362 AT NCCIH NIH HHS United States AT004418 AT NCCIH NIH HHS United (...) States P01 AT004418 AT NCCIH NIH HHS United States P01 AT004418-04 AT NCCIH NIH HHS United States AT005362 AT NCCIH NIH HHS United States K01 AT005362-02 AT NCCIH NIH HHS United States Letter Research Support, N.I.H., Extramural United States Ann Intern Med 0372351 0003-4819 0 Cholinesterase Inhibitors 0 Indans 0 Piperidines 0 Prescription Drugs 0 Tablets 8SSC91326P donepezil AIM IM Cochrane Database Syst Rev. 2006;(1):CD001190 16437430 Ann Intern Med. 2005 Sep 20;143(6):397-403 16172438 Alzheimer

Annals of Internal Medicine2011 Full Text: Link to full Text with Trip Pro

15. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. 21519001 2011 04 26 2011 06 24 2015 02 04 1526-632X 76 17 2011 Apr 26 Neurology Neurology Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. 1500-7 10.1212/WNL.0b013e318218107a The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical trial (RCT). Donepezil 10 (...) changes on other neuropsychological tests and the evaluating clinician's impression of memory change. A total of 120 participants were enrolled and randomized to either donepezil or placebo. No significant treatment effects were found between groups on either primary outcome of memory or any secondary cognitive outcomes. A trend was noted for the clinician's impression of memory change in favor of donepezil (37.7%) vs placebo (23.7%) (p = 0.097). No serious or unanticipated adverse events attributed

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

16. Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy

Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy 21199965 2011 01 04 2011 02 09 2016 12 15 1538-3636 68 1 2011 Jan Archives of general psychiatry Arch. Gen. Psychiatry Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant (...) pharmacotherapy. 51-60 10.1001/archgenpsychiatry.2010.184 Cognitive impairment in late-life depression is a core feature of the illness. To test whether donepezil hydrochloride and antidepressant therapy is superior to placebo and antidepressant therapy in improving cognitive performance and instrumental activities of daily living and in reducing recurrences of depression over 2 years of maintenance treatment. Randomized, double-blind, placebo-controlled maintenance trial. University clinic. One hundred

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

17. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in September 2016 in NICE’s guideline on dementia (CG42

National Institute for Health and Clinical Excellence - Technology Appraisals2011

18. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size 20395618 2010 05 25 2010 06 11 2016 12 15 1524-4628 41 6 2010 Jun Stroke Stroke Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. 1213-21 10.1161/STROKEAHA.109.570077 We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute (...) of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria. This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 years) with probable or possible VaD were randomized 2:1 to receive donepezil 5 mg/d or placebo. Coprimary outcome measures were scores on the Vascular-Alzheimer Disease Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

19. Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil

Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Article Text Therapeutics Atorvastatin does not slow cognitive decline in patients with mild

Evidence-Based Mental Health2010

20. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Kasuya M, Meguro K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared donepezil therapy for patients with a clinical dementia rating (CDR) of 1.0; of 0.5; or of 0.5 who were identified as converters to 1.0. The authors concluded that the annual chance of decline had to be reduced from 15% to 12%, through the detection of CRD 0.5 converters, to produce

NHS Economic Evaluation Database.2010